For the quarter ending 2025-09-30, BOLT had $8,152K increase in cash & cash equivalents over the period. -$9,804K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,144 | -19,601 |
| Depreciation and amortization | 290 | 746 |
| Stock-based compensation expense | 407 | 1,334 |
| Accretion of discount on marketable securities | 130 | 379 |
| Gain on sale of property and equipment | 0 | 288 |
| Non-cash lease expense | 636 | 1,239 |
| Prepaid expenses and other assets | 86 | 236 |
| Accounts payable and accrued expenses | -1,882 | -3,351 |
| Operating lease liabilities | -594 | -1,026 |
| Deferred revenue | -1,229 | -1,533 |
| Other long-term liabilities | 0 | 133 |
| Net cash used in operating activities | -9,732 | -22,962 |
| Purchases of property and equipment | 72 | - |
| Proceeds from sales of property and equipment | 0 | 963 |
| Purchases of marketable securities | 1,719 | 15,457 |
| Maturities of marketable securities | 19,675 | 39,838 |
| Net cash provided by investing activities | 17,884 | 25,344 |
| Proceeds from issuance of common stock | 0 | 14 |
| Net cash provided by financing activities | 0 | 14 |
| Net increase (decrease) in cash | 8,152 | 2,396 |
| Cash and cash equivalents at beginning of period | 8,970 | - |
| Cash and cash equivalents at end of period | 19,518 | - |
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)